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Abstract: There is little data on ethnic differences in incidence of DR and sight threatening DR
(STDR) in the United Kingdom. We aimed to determine ethnic differences in the development of
DR and STDR and to identify risk factors of DR and STDR in people with incident or prevalent
type II diabetes (T2DM). We used electronic primary care medical records of people registered with
134 general practices in East London during the period from January 2007–January 2017. There
were 58,216 people with T2DM eligible to be included in the study. Among people with newly
diagnosed T2DM, Indian, Pakistani and African ethnic groups showed an increased risk of DR with
Africans having highest risk of STDR compared to White ethnic groups (HR: 1.36 95% CI 1.02–1.83).
Among those with prevalent T2DM, Indian, Pakistani, Bangladeshi and Caribbean ethnic groups
showed increased risk of DR and STDR with Indian having the highest risk of any DR (HR: 1.24 95%
CI 1.16–1.32) and STDR (HR: 1.38 95% CI 1.17–1.63) compared with Whites after adjusting for all
covariates considered. It is important to optimise prevention, screening and treatment options in
these ethnic minority groups to avoid health inequalities in diabetes eye care.
Keywords: type 2 diabetes; retinopathy; ethnicity; general practice; risk factors
1. Introduction
Diabetic retinopathy (DR) is a major microvascular complication of diabetes [1,2].
DR can progress from no DR to sight threatening diabetic retinopathy (STDR) without
any symptoms [3]. In the United Kingdom (UK), the prevalence of DR and STDR among
people with type 2 diabetes (T2DM) is approximately 30% and 1.5%, respectively [4,5].
In absolute numbers, this equates to around 1.5 million people with DR and 140,000 with
STDR. In the UK, the two largest minority ethnic groups are South Asian (7.5%) and
Afro-Caribbean (3.3%) compared to the White ethnic groups who make up 86% of the
population [6]. These ethnic minority groups are likely to develop diabetes from a younger
age and have a higher prevalence of diabetes compared to the White counterparts [7–9].
Similarly, the prevalence of DR is higher in South Asian and Black ethnic groups in the UK
and these findings are consistent with global literature [4,10–16]. These ethnic differences
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in prevalence of DR are often explained by earlier age of onset of diabetes, and suboptimal
control of risk factors. However, there is little data on differences in the incidence of DR
and STDR in these ethnic groups when compared to their White counterparts. Studies on
incidence of DR and STDR are mainly reported from Clinical Practice Research Datalink
(CPRD) where ethnicity records are missing in about a third of the people with diabetes
or from regions that do not have sufficient ethnic minorities to study the incidence at a
population level [4]. It is also unclear if any ethnic differences in incident DR and STDR are
due to variations in control of modifiable systemic risk factors.
Duration of diabetes is one of the strongest risk factors of DR [17,18]. In the UK,
all people with newly diagnosed diabetes are referred for annual DR screening within
3 months of the screening programme being notified of the diagnosis [19]. People with
diabetes registered in the same practice have equal access to the same group of general
practitioners and access to care is free in the National Health Service (NHS). The population
in East London consists of a high proportion of people from ethnic minority groups. There-
fore, it is a suitable population in which to evaluate whether ethnicity is an independent
risk factor for incidence of DR and STDR.
The aim of this study was to determine ethnic differences in the development of
DR and STDR, and to identify risk factors for DR/STDR development in people with
newly diagnosed and prevalent T2DM at baseline. We focussed on the two main ethnic
minority groups, South Asian and Black and then further analysed the sub-groups of
Indian, Bangladeshi, Pakistani and Caribbean and African ethnic groups to identify the
role of ethnicity as an independent risk factor for DR/STDR.
2. Materials and Methods
The Moorfields Research Management Committee approved the use of this fully
anonymised UK dataset for model development and validation (SIVS1047) and further
ethics approval was not required. Approval was also obtained from the Caldicott guardian
of this anonymised dataset in Queen Mary University London (QMUL). Individual level pa-
tient consent was not obtained, as this was an observational study using de-identified data.
This cohort study was conducted using de-identified data from general practice
electronic health records collected in three Clinical Commissioning Groups (CCGs) in
East London, which include Newham, Tower Hamlets and City and Hackney. These data
covered more than 98% of the GP-registered population in these CCGs. The data included
demographic information, diagnoses, prescriptions, referrals, laboratory test results and
clinical values. Diagnoses, symptoms and clinical values in this dataset were recorded
using the Read code classification.
We included all adults with a diagnostic Read code for T2DM during the period
2007–2017 and aged 18+ at study entry. Study baseline was defined as the date of the initial
T2DM diagnostic read code for each person within the study start and end dates. Start date
was defined as the latest of study start date (January 2007), 12 months after the patient’s
current registration date, or the date the patient turned 18. Follow-up time end date is
defined as the earliest date of transferring out of the practice, or latest data collection date
or date of death or January 2017. People who were lost to follow up were censored at the
date they left the study. People with Type 1 diabetes, gestational diabetes, other forms of
diabetes were excluded.
People were classified as having newly diagnosed (incident) T2DM if their T2DM onset
date was the same as their initial T2DM diagnosis date within the study start and end dates.
If they had an earlier T2DM onset date than the initial T2DM diagnosis date within the
study period, they were classified as people with prevalent T2DM. Self-reported ethnicity
was identified using the relevant Office for National Statistic ethnic group classification in
the electronic health record of each patient. Ethnicity was considered in two ways. First
in three categories as White, South Asian and Black and then we further considered the
subgroups of Indian, Pakistani, Bangladeshi, African and Caribbean. Chinese, other Asian,
other Black and any other ethnic group were grouped as ‘Other’. A small proportion
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of people with missing or unknown ethnicity (1.8%) were not included in the analysis.
Socio-economic deprivation was categorised into quintiles of the Townsend score, which
is made up of unemployment, overcrowding and car ownership variables with the most
affluent in quintile 1 and most deprived in quintile 5.
The first record of any DR and any STDR were considered as the outcomes. Read
codes for classification levels of DR severity levels included both the American Academy
of Ophthalmology International Classification and UK National Screening Committee
classification [3]. Those who had severe Non-Proliferative DR, Proliferative DR, grading
classification for proliferative DR-R3 or grading classification for maculopathy-M1, were
identified as people with STDR. A person’s DR grade was defined as the DR severity level
in the worst eye.
Covariates that are commonly found to be associated with DR and STDR accord-
ing to existing literature were considered in this study [17,18], and these included age,
gender, hyperglycaemia, systolic blood pressure (SBP), duration of diabetes, body mass
index (BMI), total cholesterol, high density lipoprotein (HDL), eGFR, antidiabetic med-
ication, history of cardiovascular disease (ischaemic heart disease, heart failure, stroke,
peripheral vascular disease, cardiovascular death, Acute Myocardial Infarction, Bypass
graft/Angioplasty, Angina Pectoris, Cardiac Arrhythmia, Major ECG abnormality, Silent
Myocardial Infarction, Congestive Heart Failure, Transient Ischaemic Attack, Arterial Event
requiring surgery), statin prescription and antihypertensive medication prescription. These
covariates were measured at baseline for each individual and the closest record to the index
date (±6 months) was selected for clinical variables.
Sperate analysis were undertaken for the two groups of study population, people
with newly diagnosed and prevalent diabetes, and then for the two outcomes DR and
STDR. Univariable statistics were used to describe the baseline characteristics of the study
population overall and by ethnic group. Kaplan-Meier Survival estimates with log-rank test
were used to observe any differences in DR and STDR development over time by different
ethnic groups. Multivariable Cox regression was then used to identify any association
between the ethnic groups and development of any DR or STDR. Cox regression models
were developed separately among people with newly diagnosed and prevalent diabetes for
the two outcomes of DR and STDR resulting four models. All four models were adjusted
for all covariates considered in the study, and the effects of each covariate was reported
with hazard ratios (HR) with 95% confidence intervals (CI). Risk factors for development of
DR were identified using the statistical significance of each covariate in each fully adjusted
model (p < 0.05). We further analysed the ethnic differences in developing DR/STDR
by stratifying the exposure variable into the more detailed ethnic categories of Indian,
Pakistani, Bangladeshi and African and Caribbean. All statistical analyses were performed
using Stata V.16.
3. Results
3.1. Overall Study Population
There were 71,406 people with a T2DM record within the study period who were
registered with a GP practice for at least one year period. Of these, we excluded those who
had background retinopathy (n = 6926) and sight threatening retinopathy (n = 409) before
the baseline. People who had history of anti-diabetic treatment before their T2DM onset
date (n = 3318) and people who were prescribed two antidiabetic drugs or insulin on the
T2DM diagnosis date (n = 1466) were excluded and these were defined as coding errors.
Of the remaining 59,287 people, ethnicity was recorded on 98% people and there were only
1071 (2%) who did not have their ethnicity recorded (unknown or missing) and these were
also excluded, leaving 58,216 people eligible to be included in the study of whom 32,652
were people with newly diagnosed T2DM and 25,564 people with prevalent T2DM at the
study baseline with mean duration of diabetes 7.4 (SD 6.1) years.
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3.2. Baseline Characteristics of the Study Population
The following results are presented separately for groups of study population with
newly diagnosed type 2 diabetes (Table 1) and prevalent T2DM at baseline (Table 2). Among
people with newly diagnosed T2DM, we observed incidence rates of 82.8 and 4.2 events
per 1000 person years for DR and STDR, respectively. Among people with known T2DM,
the incidence rates for DR and STDR were 135.4 and 16.0 events per 1000 person years,
respectively (Table 3).
Table 1. Baseline characteristics of the study population—People with newly diagnosed type 2 diabetes.
Whole Population White South Asian Black Other
N = 32,652 N = 8727 N = 15,291 N = 6639 N = 1995
>Age at T2DM diagnosis,
years
<45 10,136 (31.0) 1423 (16.3) 6536 (42.7) 1678 (25.3) 499 (25.0)
45 to <55 9352 (28.6) 2258 (25.9) 4329 (28.3) 2176 (32.8) 589 (29.5)
55 to <65 6789 (20.8) 2360 (27.0) 2530 (16.6) 1369 (20.6) 530 (26.6)
65 to <75 4091 (12.5) 1622 (18.6) 1269 (8.3) 947 (14.3) 253 (12.7)
75+ 2284 (6.9) 1064 (12.2) 627 (4.1) 469 (7.1) 124 (6.2)
Gender
Male 18,332 (56.1) 5064 (58.0) 8842 (57.8) 3381 (50.9) 1045 (52.4)
Female 14,320 (43.8) 3663 (41.9) 6449 (42.2) 3258 (49.1) 950 (47.7)
Townsend Score (quintiles)
1 (most affluent) 6874 (21.0) 1484 (17.0) 4043 (26.4) 978 (14.7) 369 (18.5)
2 6795 (20.8) 1766 (20.2) 3159 (20.7) 1425 (21.5) 445 (22.3)
3 6409 (19.6) 1931 (22.1) 2708 (17.7) 1369 (20.6) 401 (20.1)
4 6335 (19.4) 1774 (20.3) 2807 (18.4) 1390 (20.9) 364 (18.3)
5 (most deprived) 6130 (18.8) 1739 (19.9) 2535 (16.6) 1448 (21.8) 408 (20.4)
Not recorded 109 (0.3) 33 (0.4) 39 (0.3) 29 (0.4) 8 (0.4)
Body Mass Index (kg/m2)
<18.5 321(1.0) 71 (0.8) 167 (1.1) 51 (0.8) 32 (1.6)
18.5 to <25 4627 (14.2) 686 (7.9) 3002 (19.6) 610 (9.2) 329 (16.5)
25 to <30 10,979 (33.7) 1990 (22.8) 6381 (41.7) 1951 (29.4) 657 (32.9)
≥30 14067 (43.1) 5094 (58.4) 4706 (30.8) 3494 (52.6) 773 (38.7)
Not recorded 2658 (8.2) 886 (10.2) 1035 (6.8) 533 (8.0) 204 (10.3)
HbA1c (mmol/mol)
<50 6927 (21.2) 2198 (25.2) 2912 (19.0) 1399 (21.1) 418 (20.9)
50 to <100 18, 368 (56.2) 4626 (53.0) 9002 (58.9) 3602 (54.3) 1138 (57.0)
≥100 2561 (7.8) 627 (7.6) 970 (6.3) 795 (11.9) 169 (8.5)
Not recorded 4796 (14.7) 1276 (14.6) 2407 (15.7) 843 (12.7) 270 (13.5)
Systolic Blood Pressure
(mmHg)
<120 6396 (19.6) 1224 (14.0) 3897 (25.5) 918 (13.8) 357 (17.9)
120 to <130 7537 (23.1) 1891 (21.7) 3865 (25.3) 1315 (20.2) 430 (21.6)
130 to <140 8468 (25.9) 2404 (27.5) 3756 (24.6) 1792 (27.0) 516 (25.8)
≥140 9273 (28.4) 2943 (33.7) 3348 (22.0) 2367 (35.6) 615 (30.8)
Not recorded 978 (3.0) 265 (3.0) 425 (2.8) 211 (3.2) 77 (3.9)
Total Cholesterol (mmol/L)
<5.2 17,072 (52.3) 4537 (52.0) 8221 (53.8) 3351 (50.5) 963 (48.3)
5.2 to <6.2 8188 (25.1) 2068 (23.7) 3898 (25.5) 1719 (25.9) 503 (25.2)
≥6.2 5413 (16.6) 1542 (17.7) 2359 (15.4) 1127 (16.8) 385 (19.3)
Not recorded 1979 (6.1) 580 (6.6) 813 (5.3) 442 (6.7) 144 (7.2)
eGFR (mL/min/1.73m2)
<60 2546 (7.8) 939 (10.8) 738 (4.8) 747 (11.3) 122 (6.2)
≥60 27,832 (85.2) 7219 (82.7) 13,461 (88.0) 5438 (81.9) 1714 (85.9)
Not recorded 2274 (7.1) 569 (6.5) 1092 (7.1) 454 (6.8) 159 (7.9)




No 29,532 (90.4) 7339 (84.1) 14,135 (92.4) 6233 (93.8) 1825 (91.5)
Yes 3120 (9.6) 1388 (15.9) 1156 (7.4) 406 (6.2) 170 (8.5)
History of Antidiabetic 21,779 (66.7) 6002 (66.8) 10,037 (65.6) 4409 (66.4) 1331 (66.7)




No 17,620 (53.9) 3935 (45.1) 9396 (61.4) 3232 (48.7) 1057 (53.0)
Yes 15,032 (46.0) 4792 (54.9) 5895 (38.6) 3407 (51.3) 938 (47.0)
History of Statin Medication
No 6229 (19.1) 1495 (17.1) 2553 (16.7) 1749 (26.3) 432 (21.7)
Yes 26,423 (80.9) 7232 (82.9) 12,738 (83.5) 4890 (73.7) 1563 (78.3)
Abbreviations: eGFR-Estimated glomerular filtration rate. ‘Other’ group: this group included Chinese, other Asian, other Black and people
belong to any other ethnicity.
Table 2. Baseline characteristics of the study population—people with known type 2 diabetes.
Whole Population White South Asian Black Other
N = 25,564 N = 6946 N = 11,963 N = 5216 N = 1439
Age, Years
<45 4956 (19.4) 738 (10.6) 3055 (25.5) 923 (17.7) 243 (16.9)
45 to <55 6207 (24.3) 1357 (19.5) 3297 (27.5) 1213 (23.3) 340 (23.7)
55 to <65 5860 (22.9) 1827 (26.3) 2495 (20.8) 1134 (21.7) 404 (28.0)
65 to <75 5407 (21.1) 1628 (23.4) 2218 (18.5) 1258 (24.1) 303 (21.0)
75+ 3134 (12.2) 1396 (20.1) 901 (7.5) 688 (13.2) 149 (10.3)
Duration of Diabetes
0 to <2 years (ref) 4030 (15.8) 1089 (15.7) 1875 (15.7) 806 (15.5) 260 (18.1)
2 to <5 years 6835 (26.7) 1891 (27.2) 3177 (26.6) 1368 (26.2) 399 (27.7)
5 to <10 years 8125 (31.8) 2281 (32.8) 3799 (31.7) 1642 (31.5) 403 (28.0)
≥10 years 6574 (25.7) 1685 (24.3) 3112 (26.0) 1400 (26.8) 377 (26.1)
Gender
Male 13,289 (51.9) 3724 (53.6) 6333 (52.9) 2524 (48.4) 708 (49.2)
Female 12,275 (48.0) 3222 (46.4) 5630 (47.1) 2692 (51.6) 731 (50.8)
Townsend Score (quintiles)
1 4812 (18.8) 1016 (14.6) 2774 (23.2) 762 (14.6) 260 (18.0)
2 4840 (18.9) 1270 (18.3) 2264 (18.9) 1021 (19.6) 285 (19.8)
3 5110 (20.0) 1622 (23.4) 2161 (18.3) 1036 (19.9) 291 (20.2)
4 5366 (20.9) 1537 (22.1) 2432 (20.3) 1151 (22.1) 246 (17.1)
5 5373 (21.0) 1488 (21.4) 2307 (19.3) 1227 (23.5) 351 (24.4)
Not recorded 63 (0.3) 13 (0.2) 25 (0.2) 19 (0.4) 6 (0.4)
Body Mass Index (kg/m2)
<18.5 389 (1.5) 83 (1.2) 216 (1.8) 56 (1.1) 34 (2.4)
18.5 to <25 4608 (18.0) 646 (9.3) 2999 (25.1) 675 (12.9) 288 (20.0)
25 to <30 8745 (34.2) 1778 (25.6) 4788 (40.0) 1723 (33.0) 456 (31.6)
≥30 8966 (35.1) 3466 (49.9) 2814 (23.5) 2191 (42.0) 495 (34.4)
Not recorded 2856 (11.2) 973 (14.0) 1146 (9.6) 571 (10.9) 166 (11.5)
HbA1c (mmol/mol)
<50 5692 (22.3) 1897 (27.3) 2307 (19.3) 1177 (22.6) 312 (21.7)
50 to <100 15,362 (60.1) 3794 (54.6) 7701 (64.4) 3005 (57.6) 862 (59.9)
≥100 1644 (6.4) 373 (5.4) 702 (5.8) 474 (9.1) 95 (6.6)
Not recorded 2866 (11.2) 882 (12.7) 1254 (10.5) 560 (10.7) 170 (11.8)
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Table 2. Cont.
Systolic Blood Pressure (mmHg)
<120 5347 (20.9) 1129 (16.2) 3166 (26.5) 774 (14.8) 279 (19.4)
120 to <130 5733 (22.4) 1436 (20.7) 2945 (24.6) 1058 (20.3) 294 (20.5)
130 to <140 6313 (24.7) 1887 (27.2) 2699 (22.5) 1365 (26.2) 362 (25.2)
≥140 7600 (29.7) 2318 (33.3) 2929 (24.5) 1881 (36.0) 472 (32.7)
Not recorded 571 (2.2) 176 (2.5) 225 (1.9) 138 (2.7) 32 (2.2)
Total Cholesterol (mmol/L)
<5.2 18,456 (72.2) 4904 (70.6) 8949 (74.8) 3605 (69.1) 998 (69.4)
5.2 to <6.2 3237 (12.7) 883 (12.7) 1388 (11.6) 767 (14.7) 199 (13.8)
≥6.2 1643 (6.4) 465 (6.7) 677 (5.7) 376 (7.2) 125 (8.7)
Not recorded 2228 (8.7) 694 (9.9) 949 (7.9) 468 (8.9) 117 (8.1)
eGFR (mL/min/1.73m2)
<60 2978 (11.7) 1036 (14.9) 1126 (9.4) 678 (13.0) 138 (9.6)
≥60 20,160 (78.8) 5140 (74.0) 9813 (82.0) 4039 (77.4) 1168 (81.2)
Not recorded 2426 (9.5) 770 (11.1) 1024 (8.6) 499 (9.6) 133 (9.2)
History of Cardiovascular
Disease
No 21,734 (85.0) 5474 (78.8) 10,338 (86.4) 4669 (89.5) 1253 (87.1)
Yes 3830 (15.0) 1472 (21.2) 1625 (13.6) 547 (10.5) 186 (12.9)
History of Antidiabetic Drugs
No drug 4470 (17.5) 1508 (21.7) 1750 (14.6) 954 (18.3) 258 (17.9)
One drug 7244 (28.3) 1988 (28.6) 3414 (28.5) 1403 (26.9) 439 (30.5)
Two drugs 9356 (36.6) 2242 (32.3) 4781 (40.0) 1832 (35.1) 501 (34.8)
Insulin 4494 (17.6) 1208 (17.4) 2018 (16.9) 1027 (19.7) 241 (16.8)
History of Antihypertensive
Medication
No 8880 (34.7) 2003 (28.8) 4562 (38.1) 1770 (33.9) 545 (37.9)
Yes 16,684 (65.3) 4943 (71.2) 7401 (61.9) 3446 (66.1) 894 (62.1)
History of Statin
Medication—ever
No 2528 (9.9) 741 (10.7) 763 (6.4) 831 (15.9) 193 (13.4)
Yes 23,036 (90.1) 6205 (89.3) 11,200 (93.6) 4385 (84.1) 1246 (86.6)
Abbreviations: eGFR-Estimated glomerular filtration rate. ‘Other’ group: this group included Chinese, other Asian, other Black and people
belong to any other ethnicity.
Table 1 shows the characteristics of 32,652 people with newly diagnosed diabetes at
study baseline by different ethnic group. Townsend score was recorded in 99.7%, BMI was
recorded in 91% and HbA1c level was available in 85.3%, SBP was recorded in 97%, total
Cholesterol level was recorded in 94% and eGFR level was recorded in 93%. A greater
proportion of South Asians 6536 (43%) were in the <45 years age group compared with
White (16%), Black (25%) and other (25%) indicating early onset of diabetes among South
Asians. Higher proportion of South Asians were in the most affluent group 4043 (26.4%)
compared with other ethnic groups with 15–21% people in this group as shown in Table 1.
Almost 70% of people in all ethnic groups had a BMI value that was greater than 25 kg/m2.
Almost 50% of South Asians had lower blood pressure <130 mmHg compared with other
ethnic groups with a proportion of people from 34–43% in the same blood pressure group.
White ethnic groups had more than twice as high prevalence of CVD 1388 (16%) compared
to other ethnic groups with prevalence of CVD ranging from 6–8%.
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Table 3. Number of incident cases of DR/STDR during 10-year follow-up and incidence rates per 1000 person years in newly diagnosed and known T2DM at baseline.
People with Newly Diagnosed T2DM at Baseline
DR STDR















Whole Population 32,652 8638 26.5 104,257.8 82.85(81.12–84.61) 557 1.7 132,126.7 4.21 (3.88–4.58)
White 8727 2227 25.5 29,624.4 75.17(72.12–78.36) 137 1.6 37,185.5 3.68 (3.11–4.35)
South Asian 15,291 4035 26.4 47,448.6 85.04(82.45–87.70) 229 1.5 60,163.5 3.81 (3.34–4.33)
Black 6639 1833 27.6 20,953.3 87.48(83.56–91.58) 152 2.3 26,854.9 5.66 (4.83–6.63)
Other 1995 543 27.2 6231.5 87.13(80.11–94.78) 39 1.9 7922.8 4.92 (3.59–6.73)
People with Known T2DM at Baseline
DR STDR















Whole Population 25,564 12,124 47.4 89,534.1 135.41(133.02–137.84) 2200 8.6 137,140.3 16.04 (15.38–16. 72)
White 6946 2946 42.4 25,900.1 113.74(109.71–117.92) 454 6.5 37,727.6 12.03 (10.97–13.19)
South Asian 11,963 6100 50.9 40,447.5 150.81(147.07–154.64) 1145 9.6 64,136.8 17.85 (16.84–18.91)
Black 5216 2422 46.4 18,134.7 133.56(128.37–138.98) 480 9.2 27,699.3 17.32 (15.84–18.94)
Other 1439 656 45.6 5051.9 129.85(120.28–140.18) 121 8.4 7576.5 15.97 (13.36–19.08)
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Table 2 shows the baseline characteristics of 25,564 people with prevalent T2DM at the
study baseline. In this group, Townsend score was available in 99.7%, BMI was recorded
in 89%, HbA1c level was recorded in 89%, SBP was available in 98%, total Cholesterol
level was recorded in 91% and eGFR level was recorded in 91%. A greater proportion of
South Asians 3055 (25%) were in the youngest age group whereas a greater proportion
of White ethnic groups with T2DM were in the oldest age group at baseline 1396 (20%).
Duration of diabetes were similar across the ethnic groups with approximately 16% of
people in 0 to <2 years duration, 27% in the 2 to <5 years group, 31% in the 5 to <10 years
group, 26% in the >10 years group.
3.3. Kaplan Meier Plots
Figure 1 shows the Kaplan-Meier Survival estimates for DR and STDR by different
ethnic groups for newly diagnosed and people with prevalent T2DM at baseline. For DR,
there was clear separation in survival probabilities over time by each ethnic group with the
White group having a higher survival probability overtime compared to all other ethnic
groups (log rank test; p < 0.001). This separation was even more visible in people with
prevalent T2DM at baseline, White ethnic groups having the highest and South Asians
having the lowest survival probability overtime (log rank test; p < 0.001).
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For STDR, in the T2DM newly diagnosed group there was slight separation of survival
probabilities overtime by different ethnic group (log rank test; p < 0.001), but there was a
clear separation of survival probabilities among people with prevalent T2DM (log rank
test; p < 0.001) with White ethnic groups having the highest survival compared with all
other ethnic groups.
3.4. DR/STDR Events and Incidence Rate
Table 3 shows the number of incident cases of DR and STDR during the follow-up
period and the incidence rate in each cohort. Among people with newly diagnosed T2DM
at baseline, a total of 8638 people had DR events and 557 people had STDR events. For DR,
White ethnic groups had the lowest incidence rate (75.2 per 1000 person years) and Black
ethnic groups had the highest incidence rate (87.5 per 1000 person years). For STDR, White
groups had the lowest incidence rate (3.68 per 1000 person years) and Black ethnic groups
had the highest incidence rate of 5.66 per 1000 person years.
Among people with prevalent T2DM at baseline, a total of 12,124 had DR events and
2200 people had STDR events. For DR, White ethnic groups reported the lowest incidence
rate (113.7 per 1000 person years) and South Asians reported the highest incidence rate
of 150.8 per 1000 person years. In relation to STDR, White ethnic groups had the lowest
incidence rate of 12.0 per 1000 person years and South Asian had the highest incidence rate
of 17.8 per 1000 person years.
3.5. Multivariable Analysis and Ethnic Variation in Incident DR/STDR
Table 4 shows results for the multivariable Cox regression analysis for DR and STDR
outcomes. Ethnicity was significantly associated with DR and STDR in both groups of
people with newly diagnosed T2DM and prevalent T2DM at baseline after adjustment
for all the covariates considered, which include age, gender, deprivation, BMI, Hba1c,
SBP, Total Cholesterol, eGFR, history of cardiovascular disease, history of antidiabetic,
antihypertensive and statin medication use.
Table 4. Multivariable Cox regression analysis of outcome measures in newly diagnosed diabetes—Newly diagnosed T2DM Cases.
DR STDR
Adjusted HR p Value Adjusted HR p Value
Ethnic Group
White (ref) 1 1
South Asian
Indian 1.10 (1.01–1.19) 0.029 0.86 (0.60–1.21) 0.377
Pakistani 1.14 (1.03–1.25) 0.011 1.36 (0.95–1.94) 0.094
Bangladeshi 1.02 (0.95–1.09) 0.733 0.80 (0.61–1.05) 0.107
Black
Caribbean 1.07 (0.98–1.17) 0.178 1.18 (0.85–1.65) 0.315
African 1.16 (1.07–1.26) <0.001 1.36 (1.02–1.83) 0.039
Mixed and other
Mixed 1.02 (0.86–1.21) 0.878 1.37 (0.76–2.48) 0.296
Other 1.10 (1.03–1.19) 0.012 1.26 (0.95–1.67) 0.108
Age at Study Entry, Years
<45 1.21 (1.09–1.35) 0.001 0.84 (0.56–1.25) 0.392
45–54 1.15 (1.04–1.27) 0.011 0.98 (0.67–1.43) 0.897
55–64 1.10 (0.99–1.22) 0.089 0.79 (0.54–1.17) 0.236




Male 1.12(1.07–1.17) <0.001 1.22 (1.02–1.47) 0.001
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Table 4. Cont.
Townsend Score (quintiles)
1 (affluent) 1 1
2 0.93 (0.88–1.00) 0.028 0.83 (0.63–1.09) 0.176
3 0.95 (0.88–1.01) 0.072 1.05 (0.80–1.38) 0.724
4 0.95 (0.89–1.02) 0.105 1.24 (0.96–1.62) 0.104
5 (deprived) 0.90 (0.84–0.97) 0.002 1.18 (0.90–1.54) 0.229
Not recorded 0.58 (0.38–0.90) 0.015 0.51 (0.07–3.63) 0.497
Body Mass Index (kg/m2)
<18.5 1 1
18.5–25 1.00 (0.81–1.24) 0.97 0.66 (0.37–1.17) 0.157
25–30 0.90 (0.73–1.12) 0.322 0.47 (0.27–0.82) 0.008
≥30 0.87 (0.70–1.07) 0.172 0.32 (0.18–0.57) <0.001
Not recorded 0.73 (0.58–0.91) 0.005 0.24 (0.12–0.48) <0.001
HbA1c (mmol/mol)
<50 1 1
50–99 1.19 (1.12–1.26) <0.001 1.43 (1.10–1.84) 0.007
≥100 1.70 (1.57–1.85) <0.001 3.68 (2.73–4.95) <0.001




120–129 1.05 (0.98–1.12) 0.237 1.13 (0.85–1.51) 0.385
130–140 1.07 (1.01–1.15) 0.05 1.23 (0.93–1.62) 0.147
≥140 1.25 (1.17–1.33) <0.001 1.88 (1.45–2.44) <0.001
Not recorded 0.95 (0.80–1.14) 0.551 0.98 (0.47–2.02) 0.947
Total Cholesterol (mmol/L)
<5.2 1 1
5.2- 6.1 0.97 (0.92–1.02) 0.195 0.83 (0.67–1.02) 0.081
≥6.2 1.01 (0.95–1.08) 0.795 0.94 (0.75–1.19) 0.622
Not recorded 0.91 (0.80–1.03) 0.13 1.37 (0.89–2.11) 0.149
eGFR (mL/min/1.73m2)
≥60 1 1
<60 1.09 (1.00–1.19) 0.057 1.32 (0.97–1.79) 0.077




Yes 1.05 (0.97–1.13) 0.304 1.06 (0.77–1.46) 0.722
Antidiabetic Drugs
History—ever Closest Record to
Baseline
No drug 1 1




Yes 1.02 (0.97–1.07) 0.495 0.77 (0.63–0.93) 0.008
Statin History
No 1 1
Yes 1.12 (1.07–1.18) <0.001 1.20 (0.99–1.46) 0.066
Abbreviations: eGFR-Estimated glomerular filtration rate. ‘Other’ group: this group included Chinese, other Asian, other Black and people
belong to any other ethnicity.
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Among people with newly diagnosed T2DM, Indian, Pakistani, African and ‘Other’
ethnic groups had significantly higher risk of DR compared to White ethnic groups with
African having the highest risk (HR: 1.16 95% CI 1.07–1.26) (Figure 2a). However, in relation
to STDR, only Africans (HR: 1.36; 95% CI 1.02–1.83) showed an increased risk compared to
White ethnic groups (Figure 2b).




Figure 2. Risk of DR and STDR in ethnic minorities compared to white population. 
Among those with prevalent T2DM at baseline, Indian, Pakistani, Bangladeshi and 
Caribbean ethnic groups showed an increased risk of DR compared to White ethnic 
groups with Indian having the highest risk (HR: 1.24 95% CI 1.16–1.32) (Figure 2c). In the 
same group of people, Indian, Pakistani, Bangladeshi, Caribbean and ‘other’ ethnic 
groups showed a significantly higher risk of STDR compared to White ethnic groups with 
Indians having the highest risk of STDR (HR: 1.38 95% CI 1.17–1.63). 
3.6. Other Risk Factors Contributing to DR and STDR 
There were several other risk factors that were significantly associated with DR and 




A ong those with prevalent T2D at baseline, Indian, Pakistani, Bangladeshi and
Caribbean ethnic groups showed an increased risk of DR compared to White ethnic groups
with Indian having the highest risk (HR: 1.24 95% CI 1.16–1.32) (Figure 2c). In the same
group of people, Indian, Pakistani, Bangladeshi, Caribbean and ‘other’ ethnic groups
showed a significantly higher risk of STDR compared to White ethnic groups with Indians
having the highest risk of STDR (HR: 1.38 95% CI 1.17–1.63).
3.6. Other Risk Factors Contributing to DR and STDR
There were several other risk factors that were significantly associated with DR and
STDR after adjustment for all the covariates considered in this study as given Tables 4 and 5.
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Table 5. Multivariable Cox regression analysis of outcome measures in people with known diabetes—KnownT2DM Cases.
DR STDR
Adjusted HR p Value Adjusted HR p Value
Ethnic Group
White (ref) 1 1
South Asian
Indian 1.24 (1.16–1.33) <0.001 1.39 (1.18–1.63) <0.001
Pakistani 1.20 (1.11–1.30) <0.001 1.28 (1.05–1.55) 0.016
Bangladeshi 1.11 (1.05–1.17) <0.001 1.36 (1.19–1.55) <0.001
Black
Caribbean 1.09 (1.01–1.16) 0.02 1.22 (1.04–1.43) 0.016
African 1.06 (0.98–1.14) 0.145 1.10 (0.92–1.33) 0.294
Mixed and Other
Mixed 1.10 (0.96–1.26) 0.19 1.17 (0.85–1.61) 0.328
Other 1.03 (0.97–1.11) 0.335 1.25 (1.07–1.47) 0.006
Duration of Diabetes
0 to <2 years (ref) 1 1
2 to <5 years 1.17 (1.10–1.24) <0.001 1.18 (0.99–1.40) 0.059
5 to <10 years 1.37 (1.29–1.45) <0.001 1.40 (1.18–1.66) <0.001
≥10 years 1.83 (1.71–1.96) <0.001 2.46 (2.06–2.90) <0.001
Age at Study Entry, Years
<45 1.52 (1.40–1.66) <0.001 1.68 (1.37–2.05) <0.001
45–54 1.51 (1.40–1.62) <0.001 1.91 (1.60–2.29) <0.001
55–64 1.32 (1.23–1.42) <0.001 1.41 (1.18–1.68) <0.001




Male 1.10 (1.06–1.14) <0.001 1.15 (1.06–1.26) 0.001
Townsend Score (quintiles)
1 1 1
2 0.95 (0.89–1.00) 0.067 1.06 (0.91–1.22) 0.495
3 0.97 (0.91–1.02) 0.247 1.22 (1.06–1.40) 0.005
4 0.91 (0.86–0.97) 0.003 1.22 (1.06–1.40) 0.005
5 0.95 (0.89–1.00) 0.088 1.30 (1.13–1.49) <0.001
Not recorded 0.86 (0.58–1.28) 0.462 0.46 (0.11–1.88) 0.286
Body Mass Index (kg/m2)
<18.5 1 1
18.5–25 1.03 (0.88–1.20) 0.703 0.94 (0.66–1.35) 0.756
25–30 1.00 (0.86–1.18) 0.94 0.89 (0.63–1.27) 0.551
≥30 0.91 (0.78–1.07) 0.261 0.76 (0.53–1.08) 0.132
Not recorded 0.96 (0.81–1.13) 0.63 1.06 (0.74–1.53) 0.72
HbA1c (mmol/mol)
<50 1 1
50–99 1.29 (1.23–1.36) <0.001 1.62 (1.40–1.87) <0.001
≥100 1.83 (1.69–1.98) <0.001 3.20 (2.68–3.83) <0.001
Not recorded 1.00 (0.92–1.09) 0.905 1.53 (1.25–1.88) <0.001
Systolic Blood Pressure—SBP (mmHg)
<120 1 1
120–129 1.12 (1.05–1.18) <0.001 1.26 (1.09–1.45) 0.001
130–140 1.16 (1.10–1.23) <0.001 1.34 (1.17–1.55) <0.001
≥140 1.28 (1.21–1.35) <0.001 1.80 (1.57–2.05) <0.001
Not recorded 0.97 (0.84–1.13) 0.709 1.17 (0.83–1.63) 0.356




5.2–6.1 0.96 (0.91–1.02) 0.197 1.01 (0.88–1.15) 0.871
≥6.2 0.96 (0.89–1.03) 0.233 1.04 (0.88–1.24) 0.593
Not recorded 0.99 (0.91–1.07) 0.857 1.07 (0.89–1.27) 0.473
eGFR (mL/min/1.73m2)
≥60 1 1
<60 1.10 (1.04–1.17) 0.001 1.35 (1.19–1.54) <0.001
Not recorded 1.05 (0.98–1.14) 0.178 1.10 (0.93–1.30) 0.279
History of Cardiovascular Disease
No 1 1
Yes 0.98 (0.93–1.04) 0.584 0.96 (0.85–1.08) 0.514
History of Antidiabetic Drugs History-
No drug 1 1
One drug 1.01 (0.94–1.07) 0.854 0.82 (0.68–0.98) 0.035
Two drugs 1.26 (1.18–1.34) <0.001 1.36 (1.15–1.60) <0.001
Insulin 1.77 (1.65–1.89) <0.001 2.72 (2.30–3.21) <0.001
History of Antihypertensives
No 1 1
Yes 0.99 (0.95–1.04) 0.752 1.00 (0.89–1.12) 0.993
History of Statin
No 1 1
Yes 1.07 (1.01–1.13) 0.008 0.96 (0.85–1.08) 0.519
Abbreviations: eGFR- Estimated glomerular filtration rate. ‘Other’ group: this group included Chinese, other Asian, other Black and people
belong to any other ethnicity.
Among people with newly diagnosed T2DM at baseline, those who were in age
<55 had significantly higher risk of DR compared to those who were aged 75+ (Table 4).
Men were more likely to have DR and STDR compared to women with 12% (HR: 1.12
95% CI 1.07–1.17) and 22% (HR: 1.22 95% CI 1.02–1.47) increased risk, respectively. Those
with HbA1c ≥ 100mmol/mol had highest risk of DR (HR:1.70 95% CI 1.57–1.85) and STDR
(HR: 3.68 95% CI 2.73–4.95) compared to those with HbA1c < 50 mmol/mol. People with
SBP ≥ 140mmHg had higher risk of DR (HR: 1.25 95% CI 1.17–1.33) and STDR (HR: 1.88
95% CI 1.45–2.44) compared to those with SBP < 120 mmHg. Total cholesterol, eGFR, CVD
history and history of one antidiabetic drug use were not significantly associated with the
risk of DR or STDR.
Among people with prevalent T2DM at baseline, those who had duration of ≥10 years
diabetes had the highest risk of any DR (HR: 1.83 95% CI 1.71–1.96) and STDR (HR: 2.46
95% CI 2.06–2.90) compared to those with 0 to 2 years of duration (Table 5). People aged
45–54 years had the highest risk of DR and STDR compared to those who are aged 75+. Men
had 10% (HR: 1.10 95% CI 1.06–1.14) and 15% (HR: 1.15 95% CI 1.06–1.26) increased risk
of DR and STDR compared to women, respectively. Those with HbA1c ≥ 50 mmol/mol,
SBP ≥ 120 mmHg, eGFR < 60 mL/min/1.73m2 had higher risk of DR and STDR compared
to those in HbA1c < 50 mmol/mol, SBP < 120 mmHg and eGFR ≥ 60 mL/min/1.73m2,
respectively. BMI, total cholesterol, CVD history and history of antihypertensive drugs
were not significantly associated with the risk of DR or STDR.
4. Discussion
We investigated the ethnic differences in developing DR and STDR among people
with newly diagnosed and prevalent T2DM using a primary care dataset from East London
in which more than 98% of people with T2DM had complete data on ethnicity. From this
dataset, over 58,000 people were eligible to be included in this study and among people
with newly diagnosed T2DM, we observed incidence rates of 82.8 and 4.2 events per
1000 person years for DR and STDR, respectively. Among people with prevalent T2DM,
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the incidence rates for DR and STDR were 135.4 and 16.0 events per 1000 person years,
respectively. These rates varied between different ethnic groups with higher incidence rates
among South Asians and Africans compared to White ethnic groups. South Asian and Black
ethnic groups had increased risk of any DR and STDR compared to White ethnic groups
even after adjustment for age, gender, deprivation, BMI, Hba1c, SBP, total Cholesterol,
eGFR, history of cardiovascular disease, history of antidiabetic drugs, antihypertensive
and statins. Among people with newly diagnosed T2DM, Africans were 36% more likely to
have STDR compared to White ethnic groups (HR: 1.36 95% CI 1.02–1.83). Among people
with prevalent T2DM, Indians had the highest risk of any DR with 24% increased risk
(HR: 1.24 95% CI 1.16–1.32) and STDR with 38% (HR: 1.38 95% CI 1.17–1.63) increased
risk compared with White ethnic groups after adjusting for all the covariates considered.
Overall, people with prevalent T2DM group with a mean duration 7.4 years at baseline
showed stronger association between ethnicity and DR/STDR compared to the group of
people with newly diagnosed T2DM diabetes at baseline.
In existing literature, there is only a small number of studies on incidence of DR and
STDR, and most of them do not consider ethnicity as a possible risk factor. These studies
included a UK study conducted among 1919 people with newly diagnosed diabetes and
reported that 22% of the people developed retinopathy by the end of their follow-up period
of 6 years [20]. The Liverpool Diabetes Eye Study was conducted among 4770 newly
diagnosed T2DM people and 3.9% people developed STDR by the end of their 5 year
follow-up period [21]. In another study with 16,444 people with T2DM, 16.4% developed
DR and 2.7% people developed STDR after 10 years of follow-up [22]. Two recent studies
by McKay eta al [23,24] also reported DR and STDR incidence among people with T2DM
using the CPRD dataset. The first study reported 8263 (13.8%) of DR cases and 832 (1.4%)
STDR cases during the 3.5 year and 3.8 year follow up periods, respectively. This was
equivalent to an incidence rate of 39.2 cases per 1000 person years for DR and 3.6 cases
per 1000 person years for STDR [24]. The second study assessed incidence of STDR among
those with mild non-proliferative DR and a total of 1037 (5.5%) people developed STDR
over a mean follow-up period of 3.6 (SD 2.0) years [23]. Although it is challenging to
compare these studies, the event rates of both DR and STDR were higher in our study
among both groups of people with newly diagnosed as well as prevalent diabetes at
baseline. This is likely to be due to the higher proportion of minority ethnic group in our
study population who have a higher risk of diabetes in general [7–9] as well as higher risk
of DR as shown in this study.
A study by Mathur et al. used CPRD data with a nationally representative sample
of people with T2DM in the UK and reported the difference of DR and STDR incidence
by ethnicity. According to this study, there was no statistically significant difference in
incidence of DR among ethnic minority groups compared to White ethnic groups, however
in relation to STDR, South Asians had significantly higher risk compared to White ethnic
groups (HR: 1.25 95% CI 1.00–1.56) after adjustment for age, duration of diabetes, gender,
deprivation and UK region [4]. Even though the CPRD study had assessed differences in
DR and STDR incidence by ethnicity, one of the main limitations of this dataset was poor
representation of minor ethnic groups due to lack of recording of ethnicity in CPRD data.
When we consider prevalence studies, higher prevalence of DR among South Asians
and Africans have been observed compared to White ethnic groups [25]. A study that
aimed to provide estimates of visual impairment (including DR) among people attending
DR screening in the UK in 2012, showed that South Asians (OR 1.10, 95% CI 1.02 to 1.18)
and Black ethnic groups (OR 1.79, 95CI 1.70 to 1.89) have higher prevalence of visual
impairment compared to White groups [25]. Another study from the UK on DR screen-
ing has identified younger age, social deprivation, ethnicity and duration of diabetes as
independent risk factor of non-attendance, and referable retinopathy confirmed the same
association of increase risk of referable DR among Asians (OR 1.57, 95%CI 1.43 to 1.72)
and Black (OR 1.65, 95% CI 1.49–1.83) ethnic groups compared to White groups even after
adjusting for age, gender, deprivation, diabetes duration and type [26]. All these findings
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suggest that extra efforts should be made to identify and treat STDR in these ethnic groups
and to ensure that recording of self-reported ethnic group is implemented. It is now a
contractual obligation in the 2020 general practice contract and is also a requirement of hos-
pital data [27,28]. East London general practitioners have successfully prioritised recording
of self-reported ethnic group over three decades [29].
Previous studies have suggested that higher prevalence of DR and STDR among ethnic
minorities is likely to be due to suboptimal control of risk factors, delayed attendance
at DR screening programmes and poor treatment outcomes compared to White ethnic
groups in the UK [30]. However, the role of ethnicity as an independent risk factor in
developing DR and STDR is less well-researched mainly due to the lack of data from
cohorts representing the three main ethnic groups in the UK. In this study, we’ve adjusted
for all known risk factors that are found to be associated with DR and STDR and found
that ethnicity is an independent risk factor for incident DR and STDR with higher risk
among ethnic minorities. The initial univariable analysis showed that higher proportion
of South Asians were younger, affluent and had lower blood pressure compared to other
groups. Despite these characteristics of South Asians at study baseline, adjustment for all
relevant covariates in the multivariable analysis revealed that they have a higher risk of
DR and STDR compared to Whites and other groups.
We also ensured generalisability of our study results by utilising routinely collected
data from anonymised electronic datasets of patients in the NHS in the UK. The NHS
is also free to all at the point of delivery, reducing inequalities in accessing healthcare.
Another strength of our study is that the primary care datasets we used also had more
than 98% of completeness in relation to self-reported ethnicity recording. This routinely
collected primary care data set is regularly updated and therefore can be used to provide
timely information on demographic makeup of the general population in the relevant area.
Moreover, the data used in this study was collected prospectively and therefore the data
are less likely to be affected by recall bias, or observer bias which could be issues in survey
data or retrospectively collected data.
Routinely collected primary care data only provides what is recorded by the clinician
and therefore, in this dataset some of the data might be missing if they were not recorded.
Data recording practices in general practice settings may also vary based on different
financial incentivisation packages. In addition, incomplete data and coding errors can
occur. However, we have addressed these issues by checking the data for any implausible
values and excluding them and also having missing data as a separate category within the
data analysis to keep any bias to a minimum.
5. Conclusions
Our study illustrates the higher risk of DR and STDR in people with T2DM from
ethnic minority groups. These groups also have a higher prevalence of T2DM, further
increasing their risk of DR and STDR compared to the White population. Retinopathy is
another adverse health outcome therefore that is more common in people with T2DM from
ethnic minority groups. Our findings illustrate the importance of improving the prevention,
early diagnosis and management of T2DM in the UK to reduce the burden of ill-health
from retinopathy and the other adverse outcomes of T2DM, particularly in people from
ethnic minority groups.
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